Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436852 · ClinicalTrials.gov registry record · Phase 2
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00436852 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 92 participants.
The verdict
NCT00436852, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This phase II trial is studying how well ABT-751 works in treating children with neuroblastoma that has relapsed or not responded to previous treatment. Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG ABT-751
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2007-01 |
| Est. Completion | 2015-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436852
The ClinicalTrials.gov registry entry for NCT00436852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00436852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00436852 about?
NCT00436852 is a clinical study titled "ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment". This phase II trial is studying how well ABT-751 works in treating children with neuroblastoma that has relapsed or not responded to previous treatment. Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping t...
What is the current status of trial NCT00436852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2007-01. Estimated completion is 2015-03-30.
What interventions are being tested in trial NCT00436852?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), ABT-751 (DRUG).
Who is sponsoring clinical trial NCT00436852?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.